Exploring Potential Applications of Neurofilament Light Chain in MS Prognosis and Care

Opinion
Video

This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, talk about the practical use of biomarkers in treatment decision making.

Experts discuss the use of serum NFL levels in clinical practice, focusing on diagnosis, prognosis, and treatment monitoring.

They raise questions about establishing a baseline NFL level at diagnosis and its implications. Tanuja Chitnis, MD, suggests waiting 2 to 3 months after a stable period, considering the impact of steroids used to treat attacks.

They discuss the importance of understanding baseline levels and the potential correlation with future disease progression. Ahmed Obeidat, MD, PhD, emphasizes the significance of monitoring NFL levels over time, especially post-treatment initiation. He suggests re-baselining every 3 to 6 months, helping assess treatment efficacy and potentially reconsidering the diagnosis if NFL remains persistently elevated.

Mark Freedman, MD, MSc, probes into the prognostic value of peak NFL levels, referencing data indicating a correlation with brain atrophy over 10 years. Experts note that early NFL measures provide some predictive value, but continuous monitoring may not significantly enhance prognostic models.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.

This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Recent Videos
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Kathy Zackowski, PhD, OTR
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
5 KOLs are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.